nodes	percent_of_prediction	percent_of_DWPC	metapath
Desvenlafaxine—Chills—Etoposide—testicular cancer	0.00303	0.00303	CcSEcCtD
Desvenlafaxine—Vision blurred—Cisplatin—testicular cancer	0.00303	0.00303	CcSEcCtD
Desvenlafaxine—Asthenia—Vinblastine—testicular cancer	0.00302	0.00302	CcSEcCtD
Desvenlafaxine—Tremor—Cisplatin—testicular cancer	0.00301	0.00301	CcSEcCtD
Desvenlafaxine—Alopecia—Etoposide—testicular cancer	0.00299	0.00299	CcSEcCtD
Desvenlafaxine—Nervous system disorder—Ifosfamide—testicular cancer	0.00298	0.00298	CcSEcCtD
Desvenlafaxine—Skin disorder—Ifosfamide—testicular cancer	0.00295	0.00295	CcSEcCtD
Desvenlafaxine—Hyperhidrosis—Ifosfamide—testicular cancer	0.00294	0.00294	CcSEcCtD
Desvenlafaxine—Hot flush—Epirubicin—testicular cancer	0.00293	0.00293	CcSEcCtD
Desvenlafaxine—Vomiting—Chlorambucil—testicular cancer	0.00292	0.00292	CcSEcCtD
Desvenlafaxine—Menopausal symptoms—Epirubicin—testicular cancer	0.0029	0.0029	CcSEcCtD
Desvenlafaxine—Decreased appetite—Dactinomycin—testicular cancer	0.00289	0.00289	CcSEcCtD
Desvenlafaxine—Diarrhoea—Vinblastine—testicular cancer	0.00288	0.00288	CcSEcCtD
Desvenlafaxine—Dysgeusia—Etoposide—testicular cancer	0.00288	0.00288	CcSEcCtD
Desvenlafaxine—Fatigue—Dactinomycin—testicular cancer	0.00286	0.00286	CcSEcCtD
Desvenlafaxine—Irritability—Methotrexate—testicular cancer	0.00279	0.00279	CcSEcCtD
Desvenlafaxine—Dizziness—Vinblastine—testicular cancer	0.00279	0.00279	CcSEcCtD
Desvenlafaxine—Convulsion—Cisplatin—testicular cancer	0.00278	0.00278	CcSEcCtD
Desvenlafaxine—Hyponatraemia—Epirubicin—testicular cancer	0.00275	0.00275	CcSEcCtD
Desvenlafaxine—Gastrointestinal haemorrhage—Epirubicin—testicular cancer	0.00274	0.00274	CcSEcCtD
Desvenlafaxine—Nausea—Chlorambucil—testicular cancer	0.00273	0.00273	CcSEcCtD
Desvenlafaxine—Paraesthesia—Ifosfamide—testicular cancer	0.00273	0.00273	CcSEcCtD
Desvenlafaxine—Anxiety—Cisplatin—testicular cancer	0.00273	0.00273	CcSEcCtD
Desvenlafaxine—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—testicular cancer	0.00272	0.00272	CcSEcCtD
Desvenlafaxine—Hot flush—Doxorubicin—testicular cancer	0.00271	0.00271	CcSEcCtD
Desvenlafaxine—Somnolence—Ifosfamide—testicular cancer	0.0027	0.0027	CcSEcCtD
Desvenlafaxine—Liver function test abnormal—Methotrexate—testicular cancer	0.0027	0.0027	CcSEcCtD
Desvenlafaxine—Menopausal symptoms—Doxorubicin—testicular cancer	0.00269	0.00269	CcSEcCtD
Desvenlafaxine—Vomiting—Vinblastine—testicular cancer	0.00268	0.00268	CcSEcCtD
Desvenlafaxine—Breast disorder—Methotrexate—testicular cancer	0.00265	0.00265	CcSEcCtD
Desvenlafaxine—Vertigo—Etoposide—testicular cancer	0.00264	0.00264	CcSEcCtD
Desvenlafaxine—Decreased appetite—Ifosfamide—testicular cancer	0.00264	0.00264	CcSEcCtD
Desvenlafaxine—Headache—Vinblastine—testicular cancer	0.00264	0.00264	CcSEcCtD
Desvenlafaxine—Toxic epidermal necrolysis—Methotrexate—testicular cancer	0.00264	0.00264	CcSEcCtD
Desvenlafaxine—Gastrointestinal disorder—Ifosfamide—testicular cancer	0.00263	0.00263	CcSEcCtD
Desvenlafaxine—Fatigue—Ifosfamide—testicular cancer	0.00262	0.00262	CcSEcCtD
Desvenlafaxine—Hypersensitivity—Bleomycin—testicular cancer	0.00262	0.00262	CcSEcCtD
Desvenlafaxine—Constipation—Ifosfamide—testicular cancer	0.0026	0.0026	CcSEcCtD
Desvenlafaxine—Loss of consciousness—Etoposide—testicular cancer	0.00259	0.00259	CcSEcCtD
Desvenlafaxine—Nervous system disorder—Cisplatin—testicular cancer	0.00257	0.00257	CcSEcCtD
Desvenlafaxine—Tachycardia—Cisplatin—testicular cancer	0.00256	0.00256	CcSEcCtD
Desvenlafaxine—Asthenia—Bleomycin—testicular cancer	0.00255	0.00255	CcSEcCtD
Desvenlafaxine—Convulsion—Etoposide—testicular cancer	0.00255	0.00255	CcSEcCtD
Desvenlafaxine—Skin disorder—Cisplatin—testicular cancer	0.00255	0.00255	CcSEcCtD
Desvenlafaxine—Hyponatraemia—Doxorubicin—testicular cancer	0.00255	0.00255	CcSEcCtD
Desvenlafaxine—Hypertension—Etoposide—testicular cancer	0.00254	0.00254	CcSEcCtD
Desvenlafaxine—Gastrointestinal haemorrhage—Doxorubicin—testicular cancer	0.00254	0.00254	CcSEcCtD
Desvenlafaxine—Hyperhidrosis—Cisplatin—testicular cancer	0.00254	0.00254	CcSEcCtD
Desvenlafaxine—Liver function test abnormal—Epirubicin—testicular cancer	0.00253	0.00253	CcSEcCtD
Desvenlafaxine—Nausea—Vinblastine—testicular cancer	0.0025	0.0025	CcSEcCtD
Desvenlafaxine—Orthostatic hypotension—Epirubicin—testicular cancer	0.0025	0.0025	CcSEcCtD
Desvenlafaxine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—testicular cancer	0.00249	0.00249	CcSEcCtD
Desvenlafaxine—Breast disorder—Epirubicin—testicular cancer	0.00248	0.00248	CcSEcCtD
Desvenlafaxine—Toxic epidermal necrolysis—Epirubicin—testicular cancer	0.00247	0.00247	CcSEcCtD
Desvenlafaxine—Hypersensitivity—Dactinomycin—testicular cancer	0.00245	0.00245	CcSEcCtD
Desvenlafaxine—Asthenia—Dactinomycin—testicular cancer	0.00238	0.00238	CcSEcCtD
Desvenlafaxine—Paraesthesia—Cisplatin—testicular cancer	0.00235	0.00235	CcSEcCtD
Desvenlafaxine—Tachycardia—Etoposide—testicular cancer	0.00234	0.00234	CcSEcCtD
Desvenlafaxine—Liver function test abnormal—Doxorubicin—testicular cancer	0.00234	0.00234	CcSEcCtD
Desvenlafaxine—Skin disorder—Etoposide—testicular cancer	0.00233	0.00233	CcSEcCtD
Desvenlafaxine—Erectile dysfunction—Methotrexate—testicular cancer	0.00233	0.00233	CcSEcCtD
Desvenlafaxine—Hyperhidrosis—Etoposide—testicular cancer	0.00232	0.00232	CcSEcCtD
Desvenlafaxine—Orthostatic hypotension—Doxorubicin—testicular cancer	0.00232	0.00232	CcSEcCtD
Desvenlafaxine—Photosensitivity reaction—Methotrexate—testicular cancer	0.00231	0.00231	CcSEcCtD
Desvenlafaxine—Breast disorder—Doxorubicin—testicular cancer	0.00229	0.00229	CcSEcCtD
Desvenlafaxine—Toxic epidermal necrolysis—Doxorubicin—testicular cancer	0.00228	0.00228	CcSEcCtD
Desvenlafaxine—Decreased appetite—Cisplatin—testicular cancer	0.00228	0.00228	CcSEcCtD
Desvenlafaxine—Diarrhoea—Dactinomycin—testicular cancer	0.00227	0.00227	CcSEcCtD
Desvenlafaxine—Gastrointestinal disorder—Cisplatin—testicular cancer	0.00226	0.00226	CcSEcCtD
Desvenlafaxine—Vomiting—Bleomycin—testicular cancer	0.00226	0.00226	CcSEcCtD
Desvenlafaxine—Rash—Bleomycin—testicular cancer	0.00224	0.00224	CcSEcCtD
Desvenlafaxine—Dermatitis—Bleomycin—testicular cancer	0.00224	0.00224	CcSEcCtD
Desvenlafaxine—Hypersensitivity—Ifosfamide—testicular cancer	0.00224	0.00224	CcSEcCtD
Desvenlafaxine—Stevens-Johnson syndrome—Methotrexate—testicular cancer	0.00224	0.00224	CcSEcCtD
Desvenlafaxine—Asthenia—Ifosfamide—testicular cancer	0.00218	0.00218	CcSEcCtD
Desvenlafaxine—Photosensitivity reaction—Epirubicin—testicular cancer	0.00216	0.00216	CcSEcCtD
Desvenlafaxine—Paraesthesia—Etoposide—testicular cancer	0.00216	0.00216	CcSEcCtD
Desvenlafaxine—Weight increased—Epirubicin—testicular cancer	0.00216	0.00216	CcSEcCtD
Desvenlafaxine—Weight decreased—Epirubicin—testicular cancer	0.00214	0.00214	CcSEcCtD
Desvenlafaxine—Somnolence—Etoposide—testicular cancer	0.00214	0.00214	CcSEcCtD
Desvenlafaxine—Epistaxis—Methotrexate—testicular cancer	0.00213	0.00213	CcSEcCtD
Desvenlafaxine—Nausea—Bleomycin—testicular cancer	0.00211	0.00211	CcSEcCtD
Desvenlafaxine—Vomiting—Dactinomycin—testicular cancer	0.00211	0.00211	CcSEcCtD
Desvenlafaxine—Stevens-Johnson syndrome—Epirubicin—testicular cancer	0.00209	0.00209	CcSEcCtD
Desvenlafaxine—Rash—Dactinomycin—testicular cancer	0.00209	0.00209	CcSEcCtD
Desvenlafaxine—Decreased appetite—Etoposide—testicular cancer	0.00209	0.00209	CcSEcCtD
Desvenlafaxine—Diarrhoea—Ifosfamide—testicular cancer	0.00208	0.00208	CcSEcCtD
Desvenlafaxine—Gastrointestinal disorder—Etoposide—testicular cancer	0.00207	0.00207	CcSEcCtD
Desvenlafaxine—Fatigue—Etoposide—testicular cancer	0.00207	0.00207	CcSEcCtD
Desvenlafaxine—Constipation—Etoposide—testicular cancer	0.00205	0.00205	CcSEcCtD
Desvenlafaxine—Dizziness—Ifosfamide—testicular cancer	0.00201	0.00201	CcSEcCtD
Desvenlafaxine—Urinary tract disorder—Methotrexate—testicular cancer	0.002	0.002	CcSEcCtD
Desvenlafaxine—Photosensitivity reaction—Doxorubicin—testicular cancer	0.002	0.002	CcSEcCtD
Desvenlafaxine—Weight increased—Doxorubicin—testicular cancer	0.00199	0.00199	CcSEcCtD
Desvenlafaxine—Epistaxis—Epirubicin—testicular cancer	0.00199	0.00199	CcSEcCtD
Desvenlafaxine—Urethral disorder—Methotrexate—testicular cancer	0.00199	0.00199	CcSEcCtD
Desvenlafaxine—Weight decreased—Doxorubicin—testicular cancer	0.00198	0.00198	CcSEcCtD
Desvenlafaxine—Nausea—Dactinomycin—testicular cancer	0.00197	0.00197	CcSEcCtD
Desvenlafaxine—Stevens-Johnson syndrome—Doxorubicin—testicular cancer	0.00194	0.00194	CcSEcCtD
Desvenlafaxine—Vomiting—Ifosfamide—testicular cancer	0.00193	0.00193	CcSEcCtD
Desvenlafaxine—Hypersensitivity—Cisplatin—testicular cancer	0.00193	0.00193	CcSEcCtD
Desvenlafaxine—Rash—Ifosfamide—testicular cancer	0.00192	0.00192	CcSEcCtD
Desvenlafaxine—Dermatitis—Ifosfamide—testicular cancer	0.00192	0.00192	CcSEcCtD
Desvenlafaxine—Erythema multiforme—Methotrexate—testicular cancer	0.00192	0.00192	CcSEcCtD
Desvenlafaxine—Eye disorder—Methotrexate—testicular cancer	0.00189	0.00189	CcSEcCtD
Desvenlafaxine—Tinnitus—Methotrexate—testicular cancer	0.00189	0.00189	CcSEcCtD
Desvenlafaxine—Asthenia—Cisplatin—testicular cancer	0.00188	0.00188	CcSEcCtD
Desvenlafaxine—Cardiac disorder—Methotrexate—testicular cancer	0.00188	0.00188	CcSEcCtD
Desvenlafaxine—Urinary tract disorder—Epirubicin—testicular cancer	0.00187	0.00187	CcSEcCtD
Desvenlafaxine—Connective tissue disorder—Epirubicin—testicular cancer	0.00186	0.00186	CcSEcCtD
Desvenlafaxine—Urethral disorder—Epirubicin—testicular cancer	0.00186	0.00186	CcSEcCtD
Desvenlafaxine—Epistaxis—Doxorubicin—testicular cancer	0.00184	0.00184	CcSEcCtD
Desvenlafaxine—Angiopathy—Methotrexate—testicular cancer	0.00184	0.00184	CcSEcCtD
Desvenlafaxine—Immune system disorder—Methotrexate—testicular cancer	0.00183	0.00183	CcSEcCtD
Desvenlafaxine—Mediastinal disorder—Methotrexate—testicular cancer	0.00183	0.00183	CcSEcCtD
Desvenlafaxine—Chills—Methotrexate—testicular cancer	0.00182	0.00182	CcSEcCtD
Desvenlafaxine—Nausea—Ifosfamide—testicular cancer	0.00181	0.00181	CcSEcCtD
Desvenlafaxine—Diarrhoea—Cisplatin—testicular cancer	0.00179	0.00179	CcSEcCtD
Desvenlafaxine—Erythema multiforme—Epirubicin—testicular cancer	0.00179	0.00179	CcSEcCtD
Desvenlafaxine—Alopecia—Methotrexate—testicular cancer	0.00179	0.00179	CcSEcCtD
Desvenlafaxine—Mental disorder—Methotrexate—testicular cancer	0.00177	0.00177	CcSEcCtD
Desvenlafaxine—Eye disorder—Epirubicin—testicular cancer	0.00177	0.00177	CcSEcCtD
Desvenlafaxine—Hypersensitivity—Etoposide—testicular cancer	0.00177	0.00177	CcSEcCtD
Desvenlafaxine—Tinnitus—Epirubicin—testicular cancer	0.00177	0.00177	CcSEcCtD
Desvenlafaxine—Malnutrition—Methotrexate—testicular cancer	0.00176	0.00176	CcSEcCtD
Desvenlafaxine—Cardiac disorder—Epirubicin—testicular cancer	0.00176	0.00176	CcSEcCtD
Desvenlafaxine—Urinary tract disorder—Doxorubicin—testicular cancer	0.00173	0.00173	CcSEcCtD
Desvenlafaxine—Dysgeusia—Methotrexate—testicular cancer	0.00173	0.00173	CcSEcCtD
Desvenlafaxine—Asthenia—Etoposide—testicular cancer	0.00172	0.00172	CcSEcCtD
Desvenlafaxine—Connective tissue disorder—Doxorubicin—testicular cancer	0.00172	0.00172	CcSEcCtD
Desvenlafaxine—Angiopathy—Epirubicin—testicular cancer	0.00172	0.00172	CcSEcCtD
Desvenlafaxine—Urethral disorder—Doxorubicin—testicular cancer	0.00172	0.00172	CcSEcCtD
Desvenlafaxine—Immune system disorder—Epirubicin—testicular cancer	0.00171	0.00171	CcSEcCtD
Desvenlafaxine—Mediastinal disorder—Epirubicin—testicular cancer	0.00171	0.00171	CcSEcCtD
Desvenlafaxine—Chills—Epirubicin—testicular cancer	0.0017	0.0017	CcSEcCtD
Desvenlafaxine—Alopecia—Epirubicin—testicular cancer	0.00168	0.00168	CcSEcCtD
Desvenlafaxine—Vomiting—Cisplatin—testicular cancer	0.00167	0.00167	CcSEcCtD
Desvenlafaxine—Vision blurred—Methotrexate—testicular cancer	0.00166	0.00166	CcSEcCtD
Desvenlafaxine—Mental disorder—Epirubicin—testicular cancer	0.00166	0.00166	CcSEcCtD
Desvenlafaxine—Erythema multiforme—Doxorubicin—testicular cancer	0.00166	0.00166	CcSEcCtD
Desvenlafaxine—Rash—Cisplatin—testicular cancer	0.00165	0.00165	CcSEcCtD
Desvenlafaxine—Dermatitis—Cisplatin—testicular cancer	0.00165	0.00165	CcSEcCtD
Desvenlafaxine—Malnutrition—Epirubicin—testicular cancer	0.00165	0.00165	CcSEcCtD
Desvenlafaxine—Diarrhoea—Etoposide—testicular cancer	0.00164	0.00164	CcSEcCtD
Desvenlafaxine—Eye disorder—Doxorubicin—testicular cancer	0.00164	0.00164	CcSEcCtD
Desvenlafaxine—Tinnitus—Doxorubicin—testicular cancer	0.00164	0.00164	CcSEcCtD
Desvenlafaxine—Cardiac disorder—Doxorubicin—testicular cancer	0.00163	0.00163	CcSEcCtD
Desvenlafaxine—Tension—Epirubicin—testicular cancer	0.00162	0.00162	CcSEcCtD
Desvenlafaxine—Dysgeusia—Epirubicin—testicular cancer	0.00162	0.00162	CcSEcCtD
Desvenlafaxine—Nervousness—Epirubicin—testicular cancer	0.0016	0.0016	CcSEcCtD
Desvenlafaxine—Angiopathy—Doxorubicin—testicular cancer	0.00159	0.00159	CcSEcCtD
Desvenlafaxine—Dizziness—Etoposide—testicular cancer	0.00159	0.00159	CcSEcCtD
Desvenlafaxine—Immune system disorder—Doxorubicin—testicular cancer	0.00158	0.00158	CcSEcCtD
Desvenlafaxine—Vertigo—Methotrexate—testicular cancer	0.00158	0.00158	CcSEcCtD
Desvenlafaxine—Mediastinal disorder—Doxorubicin—testicular cancer	0.00158	0.00158	CcSEcCtD
Desvenlafaxine—Chills—Doxorubicin—testicular cancer	0.00157	0.00157	CcSEcCtD
Desvenlafaxine—Nausea—Cisplatin—testicular cancer	0.00156	0.00156	CcSEcCtD
Desvenlafaxine—Vision blurred—Epirubicin—testicular cancer	0.00156	0.00156	CcSEcCtD
Desvenlafaxine—Alopecia—Doxorubicin—testicular cancer	0.00155	0.00155	CcSEcCtD
Desvenlafaxine—Mental disorder—Doxorubicin—testicular cancer	0.00154	0.00154	CcSEcCtD
Desvenlafaxine—Convulsion—Methotrexate—testicular cancer	0.00153	0.00153	CcSEcCtD
Desvenlafaxine—Vomiting—Etoposide—testicular cancer	0.00153	0.00153	CcSEcCtD
Desvenlafaxine—Malnutrition—Doxorubicin—testicular cancer	0.00153	0.00153	CcSEcCtD
Desvenlafaxine—Rash—Etoposide—testicular cancer	0.00151	0.00151	CcSEcCtD
Desvenlafaxine—Dermatitis—Etoposide—testicular cancer	0.00151	0.00151	CcSEcCtD
Desvenlafaxine—Headache—Etoposide—testicular cancer	0.00151	0.00151	CcSEcCtD
Desvenlafaxine—Tension—Doxorubicin—testicular cancer	0.0015	0.0015	CcSEcCtD
Desvenlafaxine—Dysgeusia—Doxorubicin—testicular cancer	0.0015	0.0015	CcSEcCtD
Desvenlafaxine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.00149	0.00149	CcSEcCtD
Desvenlafaxine—Nervousness—Doxorubicin—testicular cancer	0.00148	0.00148	CcSEcCtD
Desvenlafaxine—Vertigo—Epirubicin—testicular cancer	0.00148	0.00148	CcSEcCtD
Desvenlafaxine—Syncope—Epirubicin—testicular cancer	0.00148	0.00148	CcSEcCtD
Desvenlafaxine—Palpitations—Epirubicin—testicular cancer	0.00146	0.00146	CcSEcCtD
Desvenlafaxine—Loss of consciousness—Epirubicin—testicular cancer	0.00145	0.00145	CcSEcCtD
Desvenlafaxine—Vision blurred—Doxorubicin—testicular cancer	0.00144	0.00144	CcSEcCtD
Desvenlafaxine—Convulsion—Epirubicin—testicular cancer	0.00143	0.00143	CcSEcCtD
Desvenlafaxine—Nausea—Etoposide—testicular cancer	0.00143	0.00143	CcSEcCtD
Desvenlafaxine—Hypertension—Epirubicin—testicular cancer	0.00142	0.00142	CcSEcCtD
Desvenlafaxine—Nervous system disorder—Methotrexate—testicular cancer	0.00141	0.00141	CcSEcCtD
Desvenlafaxine—Anxiety—Epirubicin—testicular cancer	0.0014	0.0014	CcSEcCtD
Desvenlafaxine—Skin disorder—Methotrexate—testicular cancer	0.0014	0.0014	CcSEcCtD
Desvenlafaxine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.0014	0.0014	CcSEcCtD
Desvenlafaxine—Hyperhidrosis—Methotrexate—testicular cancer	0.00139	0.00139	CcSEcCtD
Desvenlafaxine—Dry mouth—Epirubicin—testicular cancer	0.00137	0.00137	CcSEcCtD
Desvenlafaxine—Vertigo—Doxorubicin—testicular cancer	0.00137	0.00137	CcSEcCtD
Desvenlafaxine—Syncope—Doxorubicin—testicular cancer	0.00137	0.00137	CcSEcCtD
Desvenlafaxine—Palpitations—Doxorubicin—testicular cancer	0.00135	0.00135	CcSEcCtD
Desvenlafaxine—Loss of consciousness—Doxorubicin—testicular cancer	0.00134	0.00134	CcSEcCtD
Desvenlafaxine—Shock—Epirubicin—testicular cancer	0.00132	0.00132	CcSEcCtD
Desvenlafaxine—Convulsion—Doxorubicin—testicular cancer	0.00132	0.00132	CcSEcCtD
Desvenlafaxine—Nervous system disorder—Epirubicin—testicular cancer	0.00132	0.00132	CcSEcCtD
Desvenlafaxine—Hypertension—Doxorubicin—testicular cancer	0.00132	0.00132	CcSEcCtD
Desvenlafaxine—Tachycardia—Epirubicin—testicular cancer	0.00131	0.00131	CcSEcCtD
Desvenlafaxine—Skin disorder—Epirubicin—testicular cancer	0.00131	0.00131	CcSEcCtD
Desvenlafaxine—Hyperhidrosis—Epirubicin—testicular cancer	0.0013	0.0013	CcSEcCtD
Desvenlafaxine—Insomnia—Methotrexate—testicular cancer	0.0013	0.0013	CcSEcCtD
Desvenlafaxine—Anxiety—Doxorubicin—testicular cancer	0.0013	0.0013	CcSEcCtD
Desvenlafaxine—Paraesthesia—Methotrexate—testicular cancer	0.00129	0.00129	CcSEcCtD
Desvenlafaxine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.00129	0.00129	CcSEcCtD
Desvenlafaxine—Somnolence—Methotrexate—testicular cancer	0.00128	0.00128	CcSEcCtD
Desvenlafaxine—Dry mouth—Doxorubicin—testicular cancer	0.00127	0.00127	CcSEcCtD
Desvenlafaxine—Decreased appetite—Methotrexate—testicular cancer	0.00125	0.00125	CcSEcCtD
Desvenlafaxine—Gastrointestinal disorder—Methotrexate—testicular cancer	0.00124	0.00124	CcSEcCtD
Desvenlafaxine—Fatigue—Methotrexate—testicular cancer	0.00124	0.00124	CcSEcCtD
Desvenlafaxine—Shock—Doxorubicin—testicular cancer	0.00123	0.00123	CcSEcCtD
Desvenlafaxine—Nervous system disorder—Doxorubicin—testicular cancer	0.00122	0.00122	CcSEcCtD
Desvenlafaxine—Insomnia—Epirubicin—testicular cancer	0.00122	0.00122	CcSEcCtD
Desvenlafaxine—Tachycardia—Doxorubicin—testicular cancer	0.00122	0.00122	CcSEcCtD
Desvenlafaxine—Skin disorder—Doxorubicin—testicular cancer	0.00121	0.00121	CcSEcCtD
Desvenlafaxine—Paraesthesia—Epirubicin—testicular cancer	0.00121	0.00121	CcSEcCtD
Desvenlafaxine—Hyperhidrosis—Doxorubicin—testicular cancer	0.0012	0.0012	CcSEcCtD
Desvenlafaxine—Somnolence—Epirubicin—testicular cancer	0.0012	0.0012	CcSEcCtD
Desvenlafaxine—Decreased appetite—Epirubicin—testicular cancer	0.00117	0.00117	CcSEcCtD
Desvenlafaxine—Gastrointestinal disorder—Epirubicin—testicular cancer	0.00116	0.00116	CcSEcCtD
Desvenlafaxine—Fatigue—Epirubicin—testicular cancer	0.00116	0.00116	CcSEcCtD
Desvenlafaxine—Constipation—Epirubicin—testicular cancer	0.00115	0.00115	CcSEcCtD
Desvenlafaxine—Insomnia—Doxorubicin—testicular cancer	0.00113	0.00113	CcSEcCtD
Desvenlafaxine—Paraesthesia—Doxorubicin—testicular cancer	0.00112	0.00112	CcSEcCtD
Desvenlafaxine—Somnolence—Doxorubicin—testicular cancer	0.00111	0.00111	CcSEcCtD
Desvenlafaxine—Decreased appetite—Doxorubicin—testicular cancer	0.00108	0.00108	CcSEcCtD
Desvenlafaxine—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.00108	0.00108	CcSEcCtD
Desvenlafaxine—Fatigue—Doxorubicin—testicular cancer	0.00107	0.00107	CcSEcCtD
Desvenlafaxine—Constipation—Doxorubicin—testicular cancer	0.00107	0.00107	CcSEcCtD
Desvenlafaxine—Hypersensitivity—Methotrexate—testicular cancer	0.00106	0.00106	CcSEcCtD
Desvenlafaxine—Asthenia—Methotrexate—testicular cancer	0.00103	0.00103	CcSEcCtD
Desvenlafaxine—Hypersensitivity—Epirubicin—testicular cancer	0.000992	0.000992	CcSEcCtD
Desvenlafaxine—Diarrhoea—Methotrexate—testicular cancer	0.000985	0.000985	CcSEcCtD
Desvenlafaxine—Asthenia—Epirubicin—testicular cancer	0.000966	0.000966	CcSEcCtD
Desvenlafaxine—Dizziness—Methotrexate—testicular cancer	0.000952	0.000952	CcSEcCtD
Desvenlafaxine—Diarrhoea—Epirubicin—testicular cancer	0.000921	0.000921	CcSEcCtD
Desvenlafaxine—Hypersensitivity—Doxorubicin—testicular cancer	0.000918	0.000918	CcSEcCtD
Desvenlafaxine—Vomiting—Methotrexate—testicular cancer	0.000915	0.000915	CcSEcCtD
Desvenlafaxine—Rash—Methotrexate—testicular cancer	0.000907	0.000907	CcSEcCtD
Desvenlafaxine—Dermatitis—Methotrexate—testicular cancer	0.000907	0.000907	CcSEcCtD
Desvenlafaxine—Headache—Methotrexate—testicular cancer	0.000902	0.000902	CcSEcCtD
Desvenlafaxine—Asthenia—Doxorubicin—testicular cancer	0.000894	0.000894	CcSEcCtD
Desvenlafaxine—Dizziness—Epirubicin—testicular cancer	0.000891	0.000891	CcSEcCtD
Desvenlafaxine—Vomiting—Epirubicin—testicular cancer	0.000856	0.000856	CcSEcCtD
Desvenlafaxine—Nausea—Methotrexate—testicular cancer	0.000855	0.000855	CcSEcCtD
Desvenlafaxine—Diarrhoea—Doxorubicin—testicular cancer	0.000853	0.000853	CcSEcCtD
Desvenlafaxine—Rash—Epirubicin—testicular cancer	0.000849	0.000849	CcSEcCtD
Desvenlafaxine—Dermatitis—Epirubicin—testicular cancer	0.000848	0.000848	CcSEcCtD
Desvenlafaxine—Headache—Epirubicin—testicular cancer	0.000844	0.000844	CcSEcCtD
Desvenlafaxine—Dizziness—Doxorubicin—testicular cancer	0.000824	0.000824	CcSEcCtD
Desvenlafaxine—Nausea—Epirubicin—testicular cancer	0.0008	0.0008	CcSEcCtD
Desvenlafaxine—Vomiting—Doxorubicin—testicular cancer	0.000792	0.000792	CcSEcCtD
Desvenlafaxine—Rash—Doxorubicin—testicular cancer	0.000786	0.000786	CcSEcCtD
Desvenlafaxine—Dermatitis—Doxorubicin—testicular cancer	0.000785	0.000785	CcSEcCtD
Desvenlafaxine—Headache—Doxorubicin—testicular cancer	0.000781	0.000781	CcSEcCtD
Desvenlafaxine—Nausea—Doxorubicin—testicular cancer	0.00074	0.00074	CcSEcCtD
